Opportunities for using in silico-based extended dosing regimens for monoclonal antibody immune checkpoint inhibitors.

Peer, Cody J; Goldstein, Daniel A; Goodell, Jennifer C; Nguyen, Ryan; Figg, William D; Ratain, Mark J

Peer, Cody J; Goldstein, Daniel A; Goodell, Jennifer C; Nguyen, Ryan; Figg, William D; Ratain, Mark J.

Afiliación

Peer CJ; Clinical Pharmacology Program, National Cancer Institute, Bethesda, MD, USA.
Goldstein DA; Davidoff Cancer Center, Rabin Medical Center, Israel.
Goodell JC; Clinical Pharmacology Program, National Cancer Institute, Bethesda, MD, USA.
Nguyen R; Clinical Pharmacology Program, National Cancer Institute, Bethesda, MD, USA.
Figg WD; Clinical Pharmacology Program, National Cancer Institute, Bethesda, MD, USA.
Ratain MJ; Department of Medicine, Center for Personalized Therapeutics, and Comprehensive Cancer Center, The University of Chicago, Chicago, IL, USA.

Br J Clin Pharmacol ; 86(9): 1769-1777, 2020 09.

Article en En | MEDLINE | ID: mdl-32424951

Asunto(s)

Inhibidores de Puntos de Control Inmunológico; Receptor de Muerte Celular Programada 1; Anticuerpos Monoclonales; Teorema de Bayes; Simulación por Computador; Humanos; Inmunoterapia

Palabras clave

immune checkpoint inhibitors; oncology; therapeutic drug monitoring

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Receptor de Muerte Celular Programada 1 / Inhibidores de Puntos de Control Inmunológico Límite: Humans Idioma: En Revista: Br J Clin Pharmacol Año: 2020 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google